Cell Therapy Enforcement Discretion Ending, But US FDA Still Faces Challenge Going After Bad Actors

 
• By Sarah Karlin-Smith
Basketball on court
Stem cell experts say the ball is now in the FDA’s court to remove bad actors from the market. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies